Annals of Surgical Oncology

, Volume 14, Issue 11, pp 3054–3069 | Cite as

The Surgeon’s Role in Cancer Prevention. The Model in Colorectal Carcinoma

  • David Z. J. Chu
  • Glen Gibson
  • Donald David
  • Yun Yen


Cancer Prevention is an emerging field, capturing the old traditional concept of anticipating the development of a major disease and preventing its full impact by early detection, treatment, or aborting the tumorigenic process by a “molecular vaccine” and alleviating the full impact of the disease. Surgeons are important clinician scientists who can carry this discipline forward and develop its full potential in the clinics and in the community. Advances in molecular biology, genetics, and other technologies have permitted seminal understanding of the carcinogenic pathways and identification of targets and intermediate end points in neoplasia. In this review, we will see that we have the means of preventing significant numbers of colorectal carcinomas (CRC).


  1. 1.
    O’Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, et al. Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. Clin Cancer Res 2002; 8:314–46PubMedGoogle Scholar
  2. 2.
    Umar A, Viner JL, Richmond E, Anderson WF, Hawk ET. Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol 2002; 7:2–26PubMedGoogle Scholar
  3. 3.
    Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nature Rev 2002; 2:537–43Google Scholar
  4. 4.
    Wolff J. The Science of Cancerous Disease from Earliest Times to the Present. Watson Publishing International, 1989:3. Republished from, Vol I, Die Lehre von der Krebskrankheitvon den altenten Zeiten bis zur Gegenwart, 1907Google Scholar
  5. 5.
    Olson JS. The History of Cancer—An Annotated Bibliography. New York: Greenwood Press, 1989:41Google Scholar
  6. 6.
    Berlin NI. The conquest of cancer. Perspect Biol Med 1979; Summer 22(4):500–18Google Scholar
  7. 7.
    Gilman A, Philips FS. The biological actions and therapeutic application of β-chloroethyl amines and sulfides. Science 1946; 103:409PubMedGoogle Scholar
  8. 8.
    Schwartz LM, Woloshin S, Fowler FJ, Welch HG. Enthusiasm for cancer screening in the U.S. JAMA 2004; 291:71–8PubMedGoogle Scholar
  9. 9.
    Vainio H, Miller AB. Primary and secondary prevention in colorectal cancer. Acta Oncol 2003; 42:809–15PubMedGoogle Scholar
  10. 10.
    Levin B, Smith RA, Feldman GE, Colditz GA, Fletcher RH, Nadel M, Rothenberger DA, et al. Promoting early detection tests for colorectal carcinoma and adenomatous polyps: a framework for action: the strategic plan of the National Colorectal Cancer Roundtable. Cancer 2002; 95:1618–28PubMedGoogle Scholar
  11. 11.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M. Cancer Statistics 2007. CA Cancer J Clin 2007; 57:43–66PubMedGoogle Scholar
  12. 12.
    World Health Organization web site, http://www.who/en/ 2007
  13. 13.
    Yiu HY, Whittemore AS, Shibata A. Increasing colorectal cancer incidence rates in Japan. Int J Cancer 2004; 109:777–81PubMedGoogle Scholar
  14. 14.
    Flood DM, Weiss NS, Cook LS, Emerson JC, Schwartz SM, Potter JD. Colorectal cancer incidence in Asian migrants to the United States and their descendants. Cancer Causes Control. 2000; 11:403–11PubMedGoogle Scholar
  15. 15.
    Donaldson MS. Nutrition and cancer: A review of the evidence for an anti-cancer diet. Nutrition J 2004; 3(19):1–37Google Scholar
  16. 16.
    Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75:1027–38PubMedGoogle Scholar
  17. 17.
    Ueda E, Watanabe T, Umetami N, Ishigami H, Sasaki S, Nagawa H. Microsatellite instability of cancers and concomitant adenomas in synchronous multiple colorectal cancer patients. J Exp Clin Cancer Res 2002; 21:149–54PubMedGoogle Scholar
  18. 18.
    Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. Seminars Cancer Biol 2004; 14:473–86Google Scholar
  19. 19.
    Goel A, Arnold CN, Niedzwiecki D, Chang DK, Riciardiello L, et al. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 2003; 63:1608–14PubMedGoogle Scholar
  20. 20.
    Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999; 91:916–32PubMedGoogle Scholar
  21. 21.
    Giovannucci E, Martinez ME. Tobacco, colorectal cancer, and adenomas: a review of the evidence. J Natl Cancer Inst 1996; 88:1717–30PubMedGoogle Scholar
  22. 22.
    Terry P, Ekbom A, Lichtenstein P, Feychting M, Wolk A. Long-term tobacco smoking and colorectal cancer in a prospective cohort study. Int J Cancer 2001; 91:585–7PubMedGoogle Scholar
  23. 23.
    Colangelo LA, Gapstur SM, Gann PH, Dyer AR. Cigarette smoking and colorectal carcinoma mortality in a cohort with long-term follow-up. Cancer 2004; 100:288–93PubMedGoogle Scholar
  24. 24.
    Lieberman DA, Prindiville S, Weiss DG, Willet W. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals, JAMA 2003; 290:2959–67PubMedGoogle Scholar
  25. 25.
    McCullough ML, Giovannucci EL. Diet and cancer prevention. Oncogene 2004; 23:6349–64PubMedGoogle Scholar
  26. 26.
    Greenwald P, Clifford CK, Milner JA. Diet and cancer prevention. Eur J Cancer 2001; 37:948–65PubMedGoogle Scholar
  27. 27.
    Boyle P, Leon ME. Epidemiology of colorectal cancer. Brit Med Bull 2002; 64:1–25PubMedGoogle Scholar
  28. 28.
    MacLennan R, Macrae R, Bain C, et al. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. J Natl Cancer Inst 1995; 87:1760–66PubMedGoogle Scholar
  29. 29.
    Alberts DS, Martinez ME, Roe Dj, et al. Phoenix Colon Cancer Prevention Physicians’ Network. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. N Engl J Med 2000; 342:1156–62PubMedGoogle Scholar
  30. 30.
    Schatzkin A, Lanza E, Corle D, et al. Polyp Prevention Trial Study group. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. N Engl J Med 2000; 342:1149–55PubMedGoogle Scholar
  31. 31.
    Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie restriction, aging and cancer prevention: Mechanisms of action and applicability to humans. Ann Rev Med 2003; 54:131–52PubMedGoogle Scholar
  32. 32.
    Bingham SA, Day NE, Luben R, Rerrari P, Slimani N, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 2003; 361:1496–1501PubMedGoogle Scholar
  33. 33.
    Lipkin M. Preclinical and early human studies of calcium and colon cancer prevention. Ann NY Acad Sci 1999; 889:120–7PubMedGoogle Scholar
  34. 34.
    Friedenreich CM, Orentein MR. Physical activity and cancer prevention: Etiologic evidence and biological mechanisms. J Nutr 2002; 132:3456S–64SPubMedGoogle Scholar
  35. 35.
    Cho KR, Vogelstein B. Genetic alterations in the adenoma-carcinoma sequence. Cancer 1992; 70(6 Suppl):1727–31PubMedGoogle Scholar
  36. 36.
    Bertario L, Russo A, Sala P, Varesco L, Giarola M, et al. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003; 21:1698–707PubMedGoogle Scholar
  37. 37.
    Su LK, Kohlmann W, Ward PA, Lynch PM. Different familial adenomatous polyposis phenotypes resulting from deletions of the entire APC exon 15. Hum Genet 2002; 111:88–95PubMedGoogle Scholar
  38. 38.
    Lovig T, Melig GI, Diep CB, Thorstensen L, Norheim AS, et al. APC and CTNNB1 mutations in a large series of sporadic colorectal carcinomas stratified by the microsatellite instability status. Scand J Gastroenterol 2002; 37(10):1184–93PubMedGoogle Scholar
  39. 39.
    Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000; 9:1967–79Google Scholar
  40. 40.
    Lynch HT, Shaw MW, Magnuson CW, Larsen Al, Krush AJ. Hereditary factors in cancer. Study of two large Midwestern kindreds. Arch Intern Med 1966; 117:206–212PubMedGoogle Scholar
  41. 41.
    Peel DJ, Ziogas A, Fox EA, Gildner M, Laham E, Kolodner RD, Anton-Culver H. Characterization of hereditary nonpolyposis colorectal cancer families from a population-based series of cases. J Natl Cancer Inst 2000; 92:1517–22PubMedGoogle Scholar
  42. 42.
    Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789–99PubMedGoogle Scholar
  43. 43.
    Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003; 21:1174–9PubMedGoogle Scholar
  44. 44.
    Boland R. Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. J Clin Oncol 2007; 25:754–6PubMedGoogle Scholar
  45. 45.
    Vasen HFA, Watson P, Mecklin JP, Lynch HT, et al. New clinical criteria for HNPCC (Lynch Syndrome) proposed by the international Collaborative Group on HNPCC. Gastroenterol 1999; 116:1453–56Google Scholar
  46. 46.
    Vasen HFA, Mecklin JP, Meera KP, et al. The international collaborative Group on hereditary non-polyposis colorectal cancer (ICG-HNPCC) Dis Colon Rectum 1991; 34:424–5PubMedGoogle Scholar
  47. 47.
    Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterol 2001; 121:198–213Google Scholar
  48. 48.
    Chung DC, Turstgi AK. The hereditary nonpolyposis colorectal cancer syndrome: Genetics and clinical implications. Ann Intern Med 2003; 138:560–70PubMedGoogle Scholar
  49. 49.
    Brink M, Goeij AFPM, Weijenberg MP, Roemen GMJM, Lentjes MHFM, et al. K-ras oncogene mutations in sporadic colorectal cancer in the Netherlands Cohort Study. Carcinogenesis 2003; 24:703–10PubMedGoogle Scholar
  50. 50.
    Villa E, Dugani A, Rebecchi AM, Vignoli A, Grottola A, Buttafoco P, et al. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 1996; 110:1346–53PubMedGoogle Scholar
  51. 51.
    Sharma S, Kemeny N, Kelsen DP, Ilson D, O’Reilly E, et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol 2002; 13(7):1067–71PubMedGoogle Scholar
  52. 52.
    Salahshor S, Kressner U, Pahlman L, Glimelius B, Lindmark G, Lindblom A. Colorectal cancer with and without microsatellite instability involves different genes. Genes Chromosomes Cancer 1999; 26:247–52PubMedGoogle Scholar
  53. 53.
    Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B, et al. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 1999; 17:593–9PubMedGoogle Scholar
  54. 54.
    Roth S, Sistonen P, Salovaara R, Hemminki A, Loukola A, et al. SMAD genes in juvenile polyposis. Genes Chromosomes Cancer 1999; 26:54–61PubMedGoogle Scholar
  55. 55.
    Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998; 18:38–43PubMedGoogle Scholar
  56. 56.
    De Leng WWJ, Westerman AM, Weterman MAJ, de Rooij FWM, van Dekken H, de Goeij AFPM, et al. Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. Clin Cancer Res 2003; 9:3065–72PubMedGoogle Scholar
  57. 57.
    Furukawa T, Konishi F, Masubuchi S, Shitoh K, Nagai H, Tukamoto T. Densely methylated MLH1 promoter correlates with decreased mRNA expression in sporadic colorectal cancers. Genes Chromosomes Cancer 2002; 35:1–10PubMedGoogle Scholar
  58. 58.
    Jubb AM, Bell SM, Quirke P. Methylation and colorectal cancer. J Pathol 2001; 195:11–34Google Scholar
  59. 59.
    Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96:8681–86PubMedGoogle Scholar
  60. 60.
    Chan AO, Broaddus RR, Houlihan PS, Issa JJ, Hamilton SR, Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 2002; 160:1823–30PubMedGoogle Scholar
  61. 61.
    Jass JR, Whitehall VLJ, Young J, Leggett BA. Emerging concepts in colorectal neoplasia. Gastroenterol 2002; 123:862–76Google Scholar
  62. 62.
    Yuen ST, Chan TL, Ho JW, Chan AS, Chung LP, et al. Germline, somatic and epigenetic events underlying mismatch repair deficiency in colorectal and HNPCC-related cancers. Oncogene 2002; 21:7585–92PubMedGoogle Scholar
  63. 63.
    Parsons R, Myeroff LL, Liu B, Wilson J, Markowitz SD, Kinsler KW, et al. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res 1995; 55: 5548–50Google Scholar
  64. 64.
    Vincent F, Hagiwara K, Ke Y, Stoner GD, Demetrick DJ, Benett WP. Mutations analysis of the transforming growth factor B type II receptor in sporadic human cancers of the pancreas, liver and breast. Biochem Biophys Res Commun 1996; 223:561–4PubMedGoogle Scholar
  65. 65.
    Boland CR, Thibodeau SN, Hamilton SR, et al. A NCI workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248–57PubMedGoogle Scholar
  66. 66.
    Young J, Simms LA, Biden KG, Wynter C, Whitehall V, et al. Features of colorectal cancers with high-level MSI occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 2001; 159:2107–16PubMedGoogle Scholar
  67. 67.
    Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Eng J Med 2003; 349:247–57Google Scholar
  68. 68.
    Cappel WN, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2004; 109:468–71Google Scholar
  69. 69.
    Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004; 23:11–27PubMedGoogle Scholar
  70. 70.
    Chu DZJ, Giacco G, Martin RG, Guinee VF. The significance of synchronous carcinoma and polyps in the colon and rectum. Cancer 1986; 57:445–50PubMedGoogle Scholar
  71. 71.
    Mattar M, Frankel P, David D, Clark KO, Chu DZJ, Jian C, Yen Y. Clinicopathologic significance of synchronous and metachronous adenomas in colorectal cancer. Clin Colorectal Cancer. 2005; 5:274–8PubMedGoogle Scholar
  72. 72.
    Frederiksen CM, Knudsen S, Laurberg S, Orntoft TF. Classification of Duke’s B and C colorectal cancers using expression arrays. J Cancer Res Clin Oncol 2003; 129:263–71PubMedGoogle Scholar
  73. 73.
    Huerta S, Harris DM, Jazirchi A, Bonavida B, Elashoff D, Livingston E, Herber D. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 2003; 22:663–70PubMedGoogle Scholar
  74. 74.
    Okutsu J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, et al. Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol Cancer Therap 2002; 1:1035–42Google Scholar
  75. 75.
    Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 2002, 21:4120–28PubMedGoogle Scholar
  76. 76.
    Hendriks Y, Franken P, Kierssen JW, De Leeuw W, Wijnen J, et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol 2003; 12:50–6Google Scholar
  77. 77.
    Mariadason JM, Arango D, Corner GA, Aranes MJ, Hotchkiss KA, et al. A gene expression profile that defines colon cell maturation in vitro. Cancer Res 2002; 62:4791–4804PubMedGoogle Scholar
  78. 78.
    Iizaka M, Furukawa Y, Tsunoda T, Akashi H, Ogawa M, Nakamura Y. Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun 2002; 292:498–512PubMedGoogle Scholar
  79. 79.
    Lechner S, Muller-Ladner U, Renke B, Scholmerich J, Ruschoff J, Kullmann F. Gene expression pattern of laser microdissected colonic crypts or adenomas with low grade dysplasia. Gut 2003; 52:1148–53PubMedGoogle Scholar
  80. 80.
    Williams NS, Gaynor RB, Scoggin S, Verma U, Gokasian T. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003; 9:931–46PubMedGoogle Scholar
  81. 81.
    Zou TT, Selary FM, Xu Y, Shustova V, Yin J, Mori Y, et al. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 2002; 21:4855–62PubMedGoogle Scholar
  82. 82.
    Tureci O, Ding J, Hilton H, Bian H, Ohkawa, Braxenthaler M, et al. Computational dissection of tissue contamination for identification of colon cancer-specific expression profiles. FASEB J 2003; 17:376–85Google Scholar
  83. 83.
    Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med 2002; 137:603–12PubMedGoogle Scholar
  84. 84.
    De Jong MM, Nolte IM, Meerman FJ, van der Graaf WTA, de Vries EGE, et al. Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2002; 11:1332–52PubMedGoogle Scholar
  85. 85.
    Goodman JE, Mechanic LE, Luke BT, Ambs S, Chanock S, Harris CC. Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer 2006; 8:1790–7Google Scholar
  86. 86.
    Martinez ME, O’Brien TG, Fultz KE, Babbar N, Yerushalmi H, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. PNAS 2003; 100:7859–64PubMedGoogle Scholar
  87. 87.
    Sieber OM, Lipton L, Crabtree M, Heinimann K, Fidalgo P, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Eng J Med 2003; 348:791–9Google Scholar
  88. 88.
    Bailey LB. Folate, methyl-related nutrients, alcohol, and the MTHFR 677 C → T polymorphism affect cancer risk: intake recommendations. J Nutr 2003; 133:3748S–53SPubMedGoogle Scholar
  89. 89.
    Sporn MB. Chemoprevention of cancer. Lancet 1993; 342:1211–3PubMedGoogle Scholar
  90. 90.
    Kelloff GJ, Sigman CC, Greenwald P. Cancer chemoprevention: progress and promise. Eur J Cancer 1999; 35:1755–62PubMedGoogle Scholar
  91. 91.
    Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin 2004; 54:150–80PubMedGoogle Scholar
  92. 92.
    Sandler RS, Baron JA, Tosteson TD, Mandel JS, Haile RW. Rectal mucosal proliferation and risk of colorectal adenomas: results from a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2000; 9:653–6PubMedGoogle Scholar
  93. 93.
    Kim KP, Whitehead C, Piazza G, Wargovich MJ. Combinatorial chemoprevention: efficacy of lovostatin and exisulind on the formation and progression of aberrant crypt foci. Anticancer Res 2004; 24:1805–11PubMedGoogle Scholar
  94. 94.
    Greenberg ER, Baron JA. Aspirin and other nonsteroidal anti-inflammatory drugs as cancer-preventive agents. In Stewart BW McGregor D (ed) Principles of Chemoprevention. IARC Scientific Publication No. 139, Lyon: International Agency for Research on Cancer, 1996Google Scholar
  95. 95.
    Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal anti-inflammatory drugs. Cancer 2002; 94:950–63PubMedGoogle Scholar
  96. 96.
    Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94:252–66PubMedGoogle Scholar
  97. 97.
    Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24:83–7PubMedGoogle Scholar
  98. 98.
    Church RD, Fleshman JW, McLeod HL. Cyclooxygenase 2 inhibition in colorectal cancer therapy. Brit J Surg 2003; 90:1055–67PubMedGoogle Scholar
  99. 99.
    Arber N, Eagle CJ, Spivak J, Racz I, Diter J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355:885–95PubMedGoogle Scholar
  100. 100.
    Bertagnoli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355:873–84Google Scholar
  101. 101.
    Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790–804PubMedGoogle Scholar
  102. 102.
    Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med, 2003; 348:891–9Google Scholar
  103. 103.
    Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med, 2003; 348:883–90Google Scholar
  104. 104.
    Chan AT, Giovanucci EL, Shernhammer S, Colditz GA, Hunter FG, Willett, Fuchs: A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med. 2004; 140:157–66Google Scholar
  105. 105.
    Martinez ME, Willett WC. Calcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. Cancer Epidemiol Biomarkers Prevention, 1998; 7:163–8Google Scholar
  106. 106.
    Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, et al. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 1999; 340:101–7PubMedGoogle Scholar
  107. 107.
    Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U, Faivre J. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomized intervention trial. European Cancer Prevention Organisation Study Group. Lancet 2000; 356:1300–6PubMedGoogle Scholar
  108. 108.
    Chu D, Alberts DS, Hussey M, Meyskens F, Fenoglio-Preiser CM, et al. Supplemental calcium and colorectal adenomas in individuals with resected colorectal carcinoma: results from a SWOG feasibility study. Frontiers in Cancer Prevention Research 2006; page 174, abstract B143Google Scholar
  109. 109.
    Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354:687–696Google Scholar
  110. 110.
    Meyskens Fl, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999; 5:945–51PubMedGoogle Scholar
  111. 111.
    Pegg AE, Shantz LM, Coleman CS. Ornithine decarboxylase as a target for chemoprevention. J Cell Biochem 1995; 22 Suppl:132–38Google Scholar
  112. 112.
    Lawson KR, Ignatenko NA, Piazza GA, Cui H, Gerner EW. Influence of k-ras activation on survival responses of caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine. Cancer Epidemiol Biomarker Prev 2000; 9:1155–62Google Scholar
  113. 113.
    Jacoby RF, Cole CE, Tutsch K, Newton NA, Kelloff G, Hawk ET, Lubet RA. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 2000; 60:1864–70PubMedGoogle Scholar
  114. 114.
    Babbar N, Gerner EW. Polyamines as modifiers of genetic risk factors in human intestinal cancers. Biochem Soc Trans 2003; 31:388–92PubMedGoogle Scholar
  115. 115.
    Lu SC, Alvarez L, Huang ZZ, Chen L, An W, Corrales FJ, Avila MA, et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. PNAS 2001: 98:5560–65PubMedGoogle Scholar
  116. 116.
    Baron JA, Cole BF, Mott L, Haile R, Grau M, et al. Neoplastic and Antineoplastic effects of β-Carotene on colorectal adenoma recurrence: Results of a randomized trial. J Natl Cancer Inst 2003; 95:717–722PubMedCrossRefGoogle Scholar
  117. 117.
    Albanes D, Malila N, Taylor PR, et al. Effects of supplemental alpha-tocopherol and beta-carotene on colorectal cancer: results from a controlled trial (Finland). Cancer Causes Control 2000:11:197–205PubMedGoogle Scholar
  118. 118.
    Whanger PD. Selenium and its relationship to cancer: an update dagger. Br J Nutr 2004; 91:11–28PubMedGoogle Scholar
  119. 119.
    Seifried HE, McDonald SS, Anderson DE, Greenwald P, Milner JA. The antioxidant conundrum in cancer. Cancer Res 2003; 63:4295–8PubMedGoogle Scholar
  120. 120.
    Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF, Slate EH, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002; 11:630–9PubMedGoogle Scholar
  121. 121.
    Wingo PA, Ries LAG, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality 1973–1995. Cancer 1998; 82:1197–207PubMedGoogle Scholar
  122. 122.
    Potter JD. Hormones and colon cancer. J Natl Cancer Inst 1995; 87:1039–40PubMedGoogle Scholar
  123. 123.
    MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and estrogen replacement therapy: a meta-analysis of epidemiological studies. Med J Aust 1995; 162:491–3PubMedGoogle Scholar
  124. 124.
    Chlebowski RT, Wactowski-Wende J, Ritenbaugh C, Hubbell FA, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350:991–1004PubMedGoogle Scholar
  125. 125.
    Slattery ML, Potter JD, Curtin K, Edwards S, Ma KN, et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res 2001; 61:126–130PubMedGoogle Scholar
  126. 126.
    Trialist; Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast Cancer. Cochrane Database Syst Rev 2001; 1:CD000486Google Scholar
  127. 127.
    Kopelovich L, Crowell JA, Fay JR. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst 2003; 95:1747–57PubMedGoogle Scholar
  128. 128.
    Slaughter DP Cancer 1953; 6:963–8Google Scholar
  129. 129.
    Jothy S, Slesak B, Harlozinska A, Lapinska J, Adamiak J, Baczynski J. Field effect of human colon carcinoma on normal mucosa: relevance of carcinoembryonic antigen expression. Tumour Biol 1996; 58–64Google Scholar
  130. 130.
    Braakhuis BJM, Tabor MP, Dummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter’s concept of field cancerization: Evidence and clinical implications. Cancer Res 2003; 63:1727–30PubMedGoogle Scholar
  131. 131.
    Guo Z, Yamaguchi K, Snachez-Cepedes M, Westra WH, Koch Wm, Sidransky D. Allelic losses in Ora Test-directed biopsies of patients with prior upper aerodigestive tract malignancy. Clin Cancer Res 2001; 7:1963–68PubMedGoogle Scholar
  132. 132.
    Loeve F, Ballegooijen M, Boer R, Kuipers EJ, Habbema JDF. Colorectal cancer risk in adenoma patients: A nation-wide study. Int J Cancer 2004; 111:147–51PubMedGoogle Scholar
  133. 133.
    Itzkowitz SH, Yio X. Inflammation and cancer: IV. Colorectal cancer in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2004; 287:G7–17PubMedGoogle Scholar
  134. 134.
    Hemminski K, Li X, Czene K. Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer 2004; 108:109–14Google Scholar
  135. 135.
    van Stolk RU. Familial and inherited colorectal cancer: endoscopic screening and surveillance. Gastrointest Endosc Clin N Am 2002; 12:111–33PubMedGoogle Scholar
  136. 136.
    Grady WM. Genetic testing for high-risk colon cancer patients. Gastroenterol 2003; 124:1574–94Google Scholar
  137. 137.
    Lynch HT, de la Chapelle A. Genomic Medicine: Hereditary Colorectal Cancer. N Eng J Med 2003; 348:919–32Google Scholar
  138. 138.
    Crabtree MD, Lomlinson IP, Hodgson SV, Neale K, Phillips RK, Houlston RS. Explaining variation in familial adenomatous polyposis: relationship between genotype and phenotype and evidence for modifier genes. Gut 2002; 51:306–8Google Scholar
  139. 139.
    Giardello FM, Bresinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterol 2001; 121:198–213CrossRefGoogle Scholar
  140. 140.
    Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch Syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96:261–8PubMedCrossRefGoogle Scholar
  141. 141.
    Sayed MG, Ahmed AF, Ringold JR, Anderson ME, Bair JL, Mitros FA, Lynch HT, et al. Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis. Ann Surg Oncol 2002; 9:901–6PubMedGoogle Scholar
  142. 142.
    Lim W, Hearle N, Shah B, Murday V, Hodgson SV, Lucassen A, et al. Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. Brit J Cancer 2003; 89:308–13PubMedGoogle Scholar
  143. 143.
    Driver JA, Gaziano JM, Gelber RP, Lee IM, Buring JE, Kurth T. Development of a risk score for colorectal cancer in men. Am J Med 2007; 120:257–263PubMedGoogle Scholar
  144. 144.
    Barrett JH, Smith G, Waxman R, Gooderham N, Lightfoot T, Garner RC, et al. Investigation of interaction between N- acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carginogenesis 2003; 24:275–282Google Scholar
  145. 145.
    Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 2000; 24:137–42PubMedGoogle Scholar
  146. 146.
    Moslein G, Pistorius S, Saeger HD, Schackert HK. Preventive surgery for colon cancer in familial adenomatous polyposis and hereditary nonpolyposis and hereditary nonpolyposis colorectal cancer syndrome. Langenbecks Arch Surg 2003; 388:9–16PubMedGoogle Scholar
  147. 147.
    Lynch HT, et al. Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers? Dis Colon Rectum 1996; 39:109–110PubMedGoogle Scholar
  148. 148.
    Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome. JAMA 2006; 296:1507–17PubMedGoogle Scholar
  149. 149.
    Lynch HT, Lanspa SJ, Boman Bm, Smyrk T, Watson P, Lynch JF, et al. Hereditary nonpolyposis colorectal cancer—Lynch syndromes I and II. Gastroenterol Clin North Am 1988; 17:679–712PubMedGoogle Scholar
  150. 150.
    You YN, Lakhani VT, Wells SA. The role of prophylactic surgery in cancer prevention. World J Surg 2007; 31:450–64PubMedGoogle Scholar
  151. 151.
    Rodriguez-Bigas MA, Vasen HF, Pekka-Mecklin J, Myrhoj T, Rozen P, Bertario L, et al. Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. International Collaborative Group on HNPCC. Ann Surg 1997; 225:202–7PubMedGoogle Scholar
  152. 152.
    Walsh JME, Terdiman JP. Colorectal Cancer Screening. JAMA 2003; 289:1288–96PubMedGoogle Scholar
  153. 153.
    Jorgensen OD, Kronborg O, Fenger C. A randomized study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002; 50:29–32PubMedGoogle Scholar
  154. 154.
    Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:132–41PubMedGoogle Scholar
  155. 155.
    Levin B, Smith RA, Feldman GE, Colditz GA, Fletcher RH, Nadel M, Rothenberger DA, et al. Promoting early detection tests for colorectal carcinoma and adenomatous polyps: a framework for action: the strategic plan of the National Colorectal Cancer Roundtable. Cancer 2002; 95:1618–28PubMedGoogle Scholar
  156. 156.
    Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329:1977–81PubMedGoogle Scholar
  157. 157.
    Hoff G, Sauar J, Vatn MH, Larsen S, Langmark K, et al. Polypectomy of adenomas in the prevention of colorectal cancer: 10 years’ follow-up of the Telemark Polyp Study I. A prospective, controlled population study. Scand J Gastroenterol 1996; 31:1006–10PubMedGoogle Scholar
  158. 158.
    Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003; 348:879–80PubMedGoogle Scholar
  159. 159.
    Kushi L, Giovannucci E. Dietary fat, cancer. Am J Med 2002; 113 suppl 9B:63s–70sPubMedGoogle Scholar
  160. 160.
    Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 2002; 360:861–68PubMedGoogle Scholar
  161. 161.
    Eyre H, Kahn R, Robertson RM, et al. Preventing cancer, cardiovascular disease, and diabetes. A common agenda for the American Cancer Society, The American Diabetes Association, and the American Heart Association. Stroke 2004; 35:1999–2010PubMedGoogle Scholar
  162. 162.
    Byers T, Nestle M, McTierman A, Doyle C, Currie-Williams A, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention. CA Cancer J Clin 2002; 52:92–119PubMedGoogle Scholar
  163. 163.
    Colbert LH, Lanza E, Ballard-Barbash R, Slattery ML, Tangrea JA, et al. Adenomatous polyp recurrence and physical activity in the Polyp Prevention Trial (US). Cancer Causes Control 2002; 13:445–53PubMedGoogle Scholar
  164. 164.
    Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946–52PubMedGoogle Scholar
  165. 165.
    Grau MV, Baron JA, Sandler RS. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 2003; 95:1765–71PubMedGoogle Scholar
  166. 166.
    Cole BF, Baron JA, Sandler RS, Haile Rw, Ahnen DJ, et al. Folic acid for the prevention of colorectal adenomas. JAMA 2007; 297:2351–2359PubMedGoogle Scholar
  167. 167.
    Sabichi AL, Demierre MF, Hawk ET, Lerman CE, Lippman SM. Frontiers in cancer prevention research. Cancer Res 2003; 63:5649–55PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • David Z. J. Chu
    • 1
  • Glen Gibson
    • 2
  • Donald David
    • 3
  • Yun Yen
    • 4
  1. 1.Department of Surgery, Facey Medical GroupNational Medical CenterSan GabrielUSA
  2. 2.Department of SurgeryCity of Hope National Medical CenterDuarteUSA
  3. 3.Department of GastroenterologyCity of Hope National Medical CenterDuarteUSA
  4. 4.Department of Medical OncologyCity of Hope National Medical CenterDuarteUSA

Personalised recommendations